Clinical Trials Logo

Filter by:
NCT ID: NCT03392805 Recruiting - HIV-1-infection Clinical Trials

Infectious Diseases and Movement Program: Study of the Effects of Physical Activity on HIV Infection

PRIMO
Start date: January 1, 2016
Phase: N/A
Study type: Interventional

exercise and physical activity can have an anti-inflammatory effect, while there is evidence that a sedentary lifestyle could be the basis for the development of systemic inflammation and increased cardiovascular risk. The primary objective is to assess whether regular physical activity is able to induce a decrease in systemic immune-activation in HIV positive patients.

NCT ID: NCT03392662 Completed - Air Leakage Clinical Trials

Hemopatch Performance Evaluation: A Prospective Observational Registry

Start date: November 29, 2017
Phase:
Study type: Observational [Patient Registry]

To assess the clinical performance and safety of HEMOPATCH Sealing Hemostat in a post-marketing setting in cardiovascular, thoracic, urologic, neurological, and other general surgical procedures.

NCT ID: NCT03392376 Active, not recruiting - Delirium Clinical Trials

Agents Intervening Against Delirium in Intensive Care Unit

AID-ICU
Start date: June 13, 2018
Phase: Phase 4
Study type: Interventional

Delirium is a frequent condition in the Intensive Care Unit (ICU) with no existing evidence-based treatment. The aim of the AID-ICU study is to assess the benefits and harms of haloperidol treatment for the management of ICU acquired delirium.

NCT ID: NCT03392012 Recruiting - Clinical trials for Sedative Adverse Reaction

Effect of Sedation on Pulmonary Aeration in Children

LunSed
Start date: February 6, 2018
Phase: N/A
Study type: Observational

Pediatric sedation is an anesthesiological technique with a good safety profile, but various complications might ensure, especially from the respiratory point of view. No suggestion is available about a possible upper safety limit for the duration of sedation to limit respiratory issue. In order to address this topic, the investigators concentrated on the occurrence of hypoventilated lung areas, which is a well-known side effect of anesthesia and sedation. The investigators hypothesis that the length of sedation is correlated with the occurrence of lung atelectasis and hypoventilation. To assess lung hypoventilation the lung ultrasound will be used. Lung ultrasound will be performed immediately after the induction of sedation and immediately before sedation interruption, in children scheduled for magnetic resonance exams. The study is a prospective observational study

NCT ID: NCT03391882 Completed - Clinical trials for Motor OFF Episodes Associated With Parkinson's Disease

A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Start date: December 19, 2018
Phase: Phase 3
Study type: Interventional

A study of an investigational drug to see how it affects the people with Parkinson's Disease complicated by motor fluctuations ("OFF" Episodes) compared to an approved drug used to treat people with Parkinson's Disease complicated by motor fluctuations ("OFF" Episodes)

NCT ID: NCT03391778 Recruiting - Neoplasms Clinical Trials

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Start date: April 9, 2018
Phase: Phase 1
Study type: Interventional

This trial will evaluate long term safety of participants who have received GlaxoSmithKline (GSK) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

NCT ID: NCT03391765 Terminated - Clinical trials for Progressive Supranuclear Palsy (PSP)

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

Start date: January 24, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the long-term safety and efficacy of ABBV-8E12 (tilavonemab) in participants with progressive supranuclear palsy (PSP).

NCT ID: NCT03391466 Active, not recruiting - Clinical trials for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

ZUMA-7
Start date: January 25, 2018
Phase: Phase 3
Study type: Interventional

The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

NCT ID: NCT03391232 Completed - Colorectal Cancer Clinical Trials

PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO)

OBERTO
Start date: May 3, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II clinical trial investigates the safety, tolerability, immunogenicity and preliminary efficacy of multiple doses of PolyPEPI1018 CRC vaccine as an add-on treatment to the standard-of-care maintenance therapy in patients with metastatic colorectal cancer. Clinical responses will be evaluated by indiction of T cell responses, T lymphocyte infiltration in accessible biopsy sites, and by objective tumor responses. This study will also explore the accuracy of the predicted T cell responses in each patient using the candidate companion diagnostic test and the correlations between clinical responses and predicted T cell responses.

NCT ID: NCT03390504 Active, not recruiting - Urothelial Cancer Clinical Trials

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

THOR
Start date: March 23, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-[L]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).